Google Acadêmico | Citações: 16429 | índice h: 32 | índice i10: 482
Avaliação dos casos de osteonecrose dos maxilares associados ao uso drogas antirreabsortivas
PDF

Palavras-chave

Osteonecrose
Maxilares
Drogas antirreabsortivas
Odontologia

Como Citar

Avaliação dos casos de osteonecrose dos maxilares associados ao uso drogas antirreabsortivas. (2025). Revista Eletrônica Acervo Saúde, 25(6), e20601. https://doi.org/10.25248/reas.e20601.2025

Copyright © | Todos os direitos reservados.

A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.

Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.

Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.

Resumo

Objetivo: Avaliar os casos de osteonecrose dos maxilares associados ao uso de drogas antirreabsortivas atendidos no ambulatório de Cirurgia Bucomaxilofacial. Métodos: Estudo retrospectivo, de delineamento transversal, com abordagem quantitativa, de caráter descritivo. Os dados foram extraídos a partir de consultas aos prontuários físico, tabulados em planilhas do Microsoft Excel e analisados no Statistical Package for Social Sciences. Resultados: A amostra contou com 10 indivíduos, com prevalência do sexo feminino (90%), com faixa etária igual ou superior a 60 anos. O alendronato foi a droga mais utilizada (60%), a via oral foi a mais empregada com 90% dos casos e o tempo de exposição à medicação de 4 a 5 anos. O estágio 2 da osteonecrose prevaleceu em 60% dos indivíduos, apresentando-se como principal localização a mandíbula (80%), com abordagem por tratamentos cirúrgicos e não-cirúrgicos. Conclusão: A terapia prolongada associada a condições sistêmicas aumenta o risco do desenvolvimento da doença e tornam-se fatores agravantes no tratamento.

PDF

Referências

AMIGUES C, et al. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database. Joint Bone Spine, 2023; 90(6): 105599.

AREDE DP, et al. Osteonecrosis of the jaw with the use of bisphosphonates and treatment with laser therapy and magnetotherapy: a concise systematic review. MedNEXT Journal of Medical and Health Sciences, 2023; 4(2).

ASSILI Z, et al. A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study. Journal of Clinical Medicine, 2021; 10(11): 2390.

BANSAL H. Osteonecrose da mandíbula relacionada a medicamentos: uma atualização. Revista Nacional de Cirurgia Maxilofacial, 2022; 13(1): 5.

BEDOGNI A, et al. Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ). Oral Diseases, 2024.

BRZAK BL, et al. Osteonecrose da mandíbula. Revista Odontologia, 2023; 11(1):23.

DIAS AA, et al. A Fotobiomodulação como alternativa no tratamento da osteonecrose dos maxilares relacionada à medicamentos: uma revisão da literatura. Revista Científica FACS, 2023; 23(2): 01-09.

DIAS KS, et al. Bisphosphonate-associated osteonecrosis of the jaw in oncology patient: case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology,2024; 137(6): e247.

EGUIA A, et al. Review and update on drugs related to the development of osteonecrosis of the jaw. Medicina oral, patologia oral y cirugia bucal, 2020; 25(1): e71.

GIUDICE A, et al. The case of medication-related osteonecrosis of the jaw addressed from a pathogenic point of view. Innovative therapeutic strategies: Focus on the most recent discoveries on oral mesenchymal stem cell-derived exosomes. Pharmaceuticals, 2020; 13(12): 423.

GUPTA M, GUPTA N. Bisphosphonate Related Jaw Osteonecrosis. StatPearls Publishing; 2024.

HANNA R, et al. A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials. Pharmaceuticals, 2024; 17(8): 1011.

HOCHMULLER M. et al. Diagnóstico, tratamento e prevenção da osteonecrose maxilar relacionada a medicamentos. Revista Brasileira Multidisciplinar, 2021; 24(2):233-247.

IZZETTI R, et al. Panoramic Radiography Features of Medication‐Related Osteonecrosis of the Jaws (MRONJ). International Journal of Dentistry, 2023; 2023(1): 5358849.

KAWAHARA M, et al. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. International journal of implant dentistry,2021; 7(1): 47.

KO YY, et al. The Role of Cone Beam Computed Tomography (CBCT) in the Diagnosis and Clinical Management of Medication-Related Osteonecrosis of the Jaw (MRONJ). Diagnostics, 2024; 14(16): 1700.

KUROSHIMA S, et al. Medication‐related osteonecrosis of the jaw: a literature review and update. Genesis, 2022; 60(8-9): 23500.

KWOEN M, et al. Association between periodontal disease, tooth extraction, and medication‐related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort‐based study. Journal of Periodontology, 2023; 94(1): 98-107.

LIMONES A, et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Medicina oral, patologia oral y cirugia bucal, 2020; 25(3): e326.

LIU F, et al. Jaw osteoporosis: Challenges to oral health and emerging perspectives of treatment. Biomedicine & Pharmacotherapy, 2024; 177: 116995.

MAUCERI R, et al. Oral Squamous Cell Carcinoma Mimicking Medication-Related Osteonecrosis of the Jaws (MRONJ): A Case Series. Oral, 2021; 1(4): 326-331.

MELZER RS, et al. A retrospective study of medication-related osteonecrosis of the jaw in multiple myeloma patients. Journal of bone marrow transplantation and cellular therapy, 2023; 4(3): 209-209.

MEREY SE, et al. Pentoxifylline and Tocopherol in the Management of Stage III Medication-Related Osteonecrosis of the Jaw: A Case Report. Akdeniz Diş Hekimliği Dergisi, 2023; 2(3):162-167.

MIRELLI C, et al. Medication-related osteonecrosis of the jaw in dental practice: A retrospective analysis of data from the Milan cohort. Dentistry Journal, 2022; 10(5): 89.

MORAES CM, et al. Osteonecrose dos maxilares associada ao uso dos bisfosfonatos: revisão de literatura. Revista saúde multidisciplinar, 2020; 8(2).

MORAIS RPL, et al. IS The use of pentoxifylline and tocopherol effective in the treatment of osteoradionecrosis of the jaws or for the treatment of medication-osteonecrosis of the jaw? an overview. Journal of Stomatology, Oral and Maxillofacial Surgery, 2024;101959.

OIZUMI T, et al. Osteonecrosis of the jaw in a patient treated with alendronate and then denosumab: A case of dramatic amelioration by minocycline and then etidronate. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2025; 37(2): 348-355.

RIVAS ANM, DONAIRE, JAR. Tratamiento conservador de osteonecrosis maxilar asociada a medicamentos refractaria mediante el uso de protocolo PENTO: reporte de un caso. Odontoestomatología, 2021: 23(38).

RUAN H. et al. Medication-related osteonecrosis of the jaw: a retrospective single center study of recurrence-related factors after surgical treatment. Clinical Oral Investigations, 2024; 28(10): 1-12.

RUGGIERO SL, et al. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. Journal of oral and maxillofacial surgery, 2022 80 (5): 920-943.

ŞAHIN O, et al. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Brazilian Journal of Otorhinolaryngology, 2022; 88(4): 613-620.

SAKAMOTO Y, et al. Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study. Scientific Reports, 2023; 13(1):12890.

SANTOS WB, et al. Osteonecrose dos Maxilares associada ao uso crônico de bisfosfonatos: relato de caso. Revista Eletrônica Acervo Saúde, 2020; 12(2): e2398.

SEO DD, BORKE, JL. Medication-Related Osteonecrosis of the Jaw–2024 Update. Oral Health Dental Sci, 2024; 8(1):1-6.

SHIN JW, et al. Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw. Scientific reports, 2024; 14(1): 8744.

SRIVASTAVA A, et al. Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis. Journal of Immunotherapy and Precision Oncology, 2021; 4(4): 196-207.

STRAUB A, et al. Bone concentration of ampicillin/sulbactam: a pilot study in patients with osteonecrosis of the jaw. International Journal of Environmental Research and Public Health, 2022; 19 (22): 14917.

VELASKI DP, et al. Etiopatogenia da osteonecrose maxilar relacionada a bisfosfonatos. Biosaúde, 2020; 22(2): 84-96.

WAN JT, et al. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone research; 2020; 8(1):14.

YAROM N, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. Journal of Clinical Oncology, 2019; 37(25): 2270-2290.